The Synovasure Alpha Defensin Test is the first and only test specifically designed and validated for the diagnosis of Joint Infection. Developed to deliver accuracy, performance and ease of use.
Unparalleled Accuracy
- The Synovasure Test achieves 97% sensitivity and 96% specificity by measuring synovial fluid alpha defensin1
- Alpha defensin is an antimicrobial peptide released by neutrophils in response to pathogens
- Alpha defensin is an ideal biomarker for PJI due to the tremendous separation it achieves between positives and negatives1
Performance backed by data
In the 149 patient study1, the Synovasure Alpha Defensin Test maintained its performance in typically challenging situations such as:
- Culture Negative Infection
14 of 38 patients with PJI were culture negative and the Synovasure Alpha Defensin Test correctly identified all 14 as infected
- Systemic Inflammatory Conditions
Synovasure Alpha Defensin Test studies included patients with systemic inflammatory disease and its performance was maintained in this population
- Antibiotic Therapy
27% of patients with PJI had been treated with antibiotics prior to aspiration and the Synovasure Alpha Defensin Test was not adversely affected in this population